Navigation Links
Syndax Announces Publication of Entinostat NSCLC Data in Cancer Research

WALTHAM, Mass., Jan. 11, 2011 /PRNewswire/ -- Syndax, a clinical-stage epigenetics oncology company, announced publication of data of entinostat combined with the demethylating agent Vidaza® (azacitidine) showing effect in reducing tumor burden in differentiated tumor cells in animal tumor models of non-small cell lung cancer (NSCLC).  The data is being published in the January 15, 2011 issue of Cancer Research.

"These findings demonstrate the promise for epigenetic therapy in cancer management and provide us with important new insights to guide further development of human treatments for lung cancer," said Steven Belinsky, Ph.D., vice president for academic research, director, lung cancer program, Lovelace Respiratory Research Institute.  "Epigenetic therapy may circumvent the problem of tumor heterogeneity by inducing the re-expression of multiple tumor suppressor genes essential for abrogating cancer cell survival and proliferation."

The purpose of the study was to determine the efficacy of a demethylating agent, Vidaza, alone or in combination with a histone deacetylase inhibitor (HDACi), entinostat, on the growth of tumors engrafted in the lungs of the nude rat and on reprogramming of the epigenome.  Researchers developed an orthotopic lung cancer model in which xenografts of human lung cancer-derived cell lines are efficiently engrafted throughout the lungs of the nude rat.  The study showed that combining the HDACi entinostat with the demethylating agent Vidaza profoundly affected growth of K-ras/p53 mutant lung adenocarcinomas engrafted orthotopically in immunocompromised nude rats by targeting and ablating pleomorphic cells that occupied up to 75% of the tumor masses.

"These exciting findings of entinostat combined with Vidaza in a validated animal model of lung cancer support ongoing clinical efforts with epigenetic therapy in solid tumors and provide a foundation for identification and  development of patient  selection tools for this novel therapeutic approach," said Joanna Horobin, M.D., president and chief executive officer of Syndax.  "These results have been confirmed in a phase 2 clinical trial of entinostat and Vidaza in patients with advanced NSCLC who had progressed after a median of three prior therapies giving us hope that this combination could become a much needed treatment option in the future for this patient population."

Similar results to the response seen in this orthotopic model were seen in a phase 2 trial of Vidaza and entinostat in heavily pretreated patients with relapsed advanced  NSCLC. Progressive disease was controlled in 10 of 28 evaluable patients, including one complete response, one partial response and eight patients with disease stabilization of at least four months. These results were presented by Dr. Rosalyn Juergens from Johns Hopkins University School of Medicine at the 13th  World Conference on Lung Cancer in 2009.

About Non-Small Cell Lung Cancer (NSCLC)

Non-small cell lung cancer, a disease in which malignant cells form in the tissues of the lungs, is the most common type of lung cancer.  The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Each year there are more than 200,000 cases of newly diagnosed advanced NSCLC.  About 60% of patients present with advanced NSCLC, meaning it has spread beyond the lung, when they are seen by a doctor.  The five-year survival rate is less than 10 percent for patients with advanced NSCLC.

About Entinostat

Entinostat is an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor with a long half-life that allows for weekly or every-other-week dosing. Entinostat has shown promise in phase two randomized clinical trials and is being studied in numerous phase 2 clinical trials including a trial in advanced breast cancer patients in combination with aromatase inhibitors and in a Hodgkin's lymphoma trial as a single agent. Under a Cooperative Research and Development Agreement (CRADA) with the NCI, entinostat also is being studied in multiple types of solid tumors and hematologic cancers.

Research has shown that HDACs are involved in the expression of various genes that regulate cell growth, differentiation and apoptosis. Such genes are frequently silenced in cancer cells through the over-expression of enzymes including HDACs. HDACs are therefore recognized as promising targets for cancer treatment. Further, studies have demonstrated that HDAC inhibition can significantly enhance anti-cancer activity when used in combination with a broad range of anti-cancer agents. The potential therefore exists to overcome tumor resistance to targeted agents.

About Syndax

Syndax Pharmaceuticals, Inc. is a Waltham, MA-based, oncology-focused pharmaceutical company. Syndax is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens. Formed in 2005, the company's intellectual property is based on work from scientific founder Ronald Evans, Ph.D., recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator.  Syndax has worldwide rights to develop and commercialize entinostat and is backed by top-tier Venture Capital firms: Domain Associates, MPM Capital, Avalon, Pappas and Forward Ventures.  For more information please visit

Contact Information

E. Blair Schoeb

Syndax Pharmaceuticals, Inc Tel: 908-277-0386

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Syndax Pharmaceuticals to Present at Biotech Showcase 2011
2. Syndax Pharmaceuticals Entinostat in Combination Shows Activity in Breast Cancer
3. Syndax Pharmaceuticals Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
4. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
5. Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
6. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
7. Amarin Announces Successful Completion of Offering of American Depositary Shares
8. Celleration, Inc. Announces Close of $8 Million Series E Financing
9. RF Technologies® Announces Distributor Agreement With Universal Hospital Services
10. Nfocus Neuromedical Announces FDA 510(k) Clearance for Next Generation Device to Treat Vascular Lesions
11. Dehaier Medical Announces Participation in Arab Health 2011
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... 2016 Revolutionary technology includes multi-speaker ... , industry leaders in advanced audiology and hearing aid ... Opn ™, the world,s first internet connected hearing aid ... devices.      (Photo: ) ... of ,world firsts,: , TwinLink™ - the ...
Breaking Medicine Technology:
(Date:6/27/2016)... Overland Park, KS (PRWEB) , ... June 27, 2016 , ... ... leader in retailers of Eyeglasses . , Millions of individuals in the United ... life, eyeglasses have become a way to both correct vision and make a fashion ...
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
Breaking Medicine News(10 mins):